Comparison of operational criteria for treatment outcome in gambiense human African trypanosomiasis

被引:8
作者
Ngoyi, D. Mumba [3 ]
Lejon, V. [1 ]
N'Siesi, F. X. [2 ]
Boelaert, M. [1 ]
Buscher, P. [1 ]
机构
[1] Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium
[2] Minist Hlth, Kinshasa, DEM REP CONGO
[3] Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO
关键词
African trypanosomiasis; African sleeping sickness; Trypanosoma brucei gambiense; treatment outcome; cerebrospinal fluid; white blood cell count; sensitivity; specificity; relapse; BRUCEI-GAMBIENSE; SLEEPING SICKNESS; COMBINATION THERAPY; CEREBROSPINAL-FLUID; CLINICAL-TRIAL; MELARSOPROL; EFLORNITHINE; NIFURTIMOX; EFFICACY; SCHEDULE;
D O I
10.1111/j.1365-3156.2009.02248.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
To develop a simple and standard operational decision tool for the diagnosis of relapse after treatment for human African trypanosomiasis (HAT), by evaluating the performance of several criteria currently used by HAT control programs and research projects. We identified 10 different criteria for relapse, based on trypanosome presence and/or white blood cell count in cerebrospinal fluid, and compared their specificity, sensitivity and time to diagnosis on a data set containing 63 relapsed and 247 cured T.b. gambiense patients. At any time point, the criterion 'Trypanosomes present and/or a cerebrospinal white blood cell count >= 50/mu l' allowed accurate and timely detection of HAT relapse, irrespective of disease stage. This criterion was 13-25% more sensitive (P <= 0.013) than trypanosome detection alone and was > 97% specific. Lumbar punctures at the end of treatment and at 3-month post-treatment provided limited clinical information. Adequate detection of relapse was possible with a simple criterion but these findings should be validated in a prospective study before adoption in clinical practice.
引用
收藏
页码:438 / 444
页数:7
相关论文
共 22 条
  • [1] BALASEGARAM M, 2004, SLEEPING SICKNESS PR, P1
  • [2] Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo
    Balasegaram, Manica
    Harris, Steve
    Checchi, Francesco
    Hamel, Catherine
    Karunakara, Unni
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2006, 84 (10) : 777 - 782
  • [3] Equivalence trial of Melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness
    Bisser, Sylvie
    N'Siesi, Francois-Xavier
    Lejon, Veerle
    Preux, Pierre-Marie
    Van Nieuwenhove, Simon
    Bilenge, Constantin Miaka Mia
    Buscher, Philippe
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (03) : 322 - 329
  • [4] Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense:: a randomised trial
    Burri, C
    Nkunhu, S
    Merolle, A
    Smith, T
    Blum, J
    Brun, R
    [J]. LANCET, 2000, 355 (9213) : 1419 - 1425
  • [5] CATTAND P, 1988, B WORLD HEALTH ORGAN, V66, P83
  • [6] Evaluation of a standardized procedure for counting microscopic cells in body fluids
    Emerson, JF
    Emerson, SS
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2005, 19 (06) : 267 - 275
  • [7] Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis
    Lejon, Veerle
    Roger, Isabelle
    Ngoyi, Dieudonne Mumba
    Menten, Joris
    Robays, Jo
    N'Siesi, Francois X.
    Bisser, Sylvie
    Boelaert, Marleen
    Buscher, Philippe
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (01) : 15 - 22
  • [8] Treatment failure related to intrathecal immunoglobulin m (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness
    Lejon, Veerle
    Robays, Jo
    N'Siesi, Francois Xavier
    Mumba, Dieudonne
    Hoogstoel, Annemie
    Bisser, Sylvie
    Reiber, Hansotto
    Boelaert, Marleen
    Buscher, Philippe
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (06) : 732 - 737
  • [9] Lourie E. M., 1942, ANN TROP MED AND PARASITOL, V36, P113
  • [10] EFFICACY AND TOXICITY OF EFLORNITHINE FOR TREATMENT OF TRYPANOSOMA-BRUCEI-GAMBIENSE SLEEPING SICKNESS
    MILORD, F
    PEPIN, J
    LOKO, L
    ETHIER, L
    MPIA, B
    [J]. LANCET, 1992, 340 (8820) : 652 - 655